trending Market Intelligence /marketintelligence/en/news-insights/trending/linHFqeP7hbkCyroDDFPsw2 content esgSubNav
In This List

Astellas Pharma to transfer pain drug rights to Grünenthal

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Astellas Pharma to transfer pain drug rights to Grünenthal

Astellas Pharma Inc. said Astellas Pharma Europe Ltd. signed a definitive agreement with Grünenthal to transfer the rights for Astella's Qutenza, a pain relief patch, in Europe, the Middle East and Africa to Grünenthal.

The deal is expected to be completed in 2018.

Tokyo-based Astella's Qutenza is used for the treatment of peripheral neuropathic pain in adults.